Company Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.
The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Country | United States |
Founded | 2015 |
IPO Date | Jun 21, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 58 |
CEO | Christopher Kirk |
Contact Details
Address: 4000 Shoreline Court, Suite 300 South San Francisco, California 94080 United States | |
Phone | 650 822 5600 |
Website | kezarlifesciences.com |
Stock Details
Ticker Symbol | KZR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001645666 |
CUSIP Number | 49372L100 |
ISIN Number | US49372L1008 |
Employer ID | 47-3366145 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Christopher J. Kirk Ph.D. | Co-Founder, Chief Executive Officer and Director |
John Franklin Fowler | Co-Founder and Director |
Dr. Jack Taunton Ph.D. | Co-Founder |
Gitanjali Jain | Senior Vice President of Investor Relations and External Affairs |
Mark Schiller | Chief Legal Officer |
Joe Tedrick | Vice President of Human Resources |
Dr. Neel K. Anand Ph.D. | Senior Vice President of Research and Drug Discovery |
Zung To | Senior Vice President of Clinical Development |
Pattie Chiang | Senior Vice President and Corporate Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 14, 2024 | 8-K | Current Report |
Nov 14, 2024 | SCHEDULE 13G/A | Filing |
Nov 12, 2024 | 10-Q | Quarterly Report |
Nov 12, 2024 | 8-K | Current Report |
Oct 29, 2024 | 8-A12B/A | Filing |
Oct 28, 2024 | 8-K | Current Report |
Oct 17, 2024 | 8-A12B | Registration of securities |
Oct 17, 2024 | 8-K | Current Report |
Oct 10, 2024 | 8-K | Current Report |
Oct 8, 2024 | SC 13D | General statement of acquisition of beneficial ownership |